Management of chronic migraine
- PMID: 36216384
- DOI: 10.1136/bmj-2021-067670
Management of chronic migraine
Abstract
Chronic migraine is a neurologic disorder associated with considerable disability, lost productivity, and a profound economic burden worldwide. The past five years have seen a dramatic expansion in new treatments for this often challenging condition, among them calcitonin gene related peptide antagonists and neuromodulatory devices. This review outlines the epidemiology of and diagnostic criteria and risk factors for chronic migraine. It discusses evidence based drug and non-drug treatments, their advantages and disadvantages, and the principles of patient centered care for adults with chronic migraine, with attention to differential diagnosis and comorbidities, clinical reasoning, initiation and monitoring, cost, and availability. It discusses the international guidelines on drug treatment for chronic migraine and evaluates non-drug treatments including behavioral and complementary therapies and lifestyle modifications. Finally, it discusses the management of chronic migraine in special populations, including pediatrics, pregnancy, and older people, and considers future questions and emerging research in the field.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: none.
Similar articles
-
Migraine overview and summary of current and emerging treatment options.Am J Manag Care. 2019 Jan;25(2 Suppl):S23-S34. Am J Manag Care. 2019. PMID: 30681821 Review.
-
Chronic migraine.BMJ. 2014 Mar 24;348:g1416. doi: 10.1136/bmj.g1416. BMJ. 2014. PMID: 24662044 Review.
-
Migraine.N Engl J Med. 2017 Aug 10;377(6):553-561. doi: 10.1056/NEJMcp1605502. N Engl J Med. 2017. PMID: 28792865 Review. No abstract available.
-
The state of migraine: An update on current and emerging treatments.Aust J Gen Pract. 2021 Dec;50(12):915-921. doi: 10.31128/AJGP-01-21-5807. Aust J Gen Pract. 2021. PMID: 34845471
-
Burden of migraine and impact of emerging therapies on managed care.Am J Manag Care. 2019 Jan;25(2 Suppl):S35-S39. Am J Manag Care. 2019. PMID: 30681822 Review.
Cited by
-
Chronic Overlapping Pain Conditions in people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a sample from the Multi-site Clinical Assessment of ME/CFS (MCAM) study.BMC Neurol. 2024 Oct 18;24(1):399. doi: 10.1186/s12883-024-03872-0. BMC Neurol. 2024. PMID: 39425035 Free PMC article.
-
Risk factors affecting the therapeutic effect of onabotulinum toxin a on chronic migraine.Pain Manag. 2025 Feb;15(2):65-71. doi: 10.1080/17581869.2025.2458448. Epub 2025 Jan 27. Pain Manag. 2025. PMID: 39871598
-
RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine.Eur J Neurol. 2024 Apr;31(4):e16203. doi: 10.1111/ene.16203. Epub 2024 Jan 25. Eur J Neurol. 2024. PMID: 38270379 Free PMC article.
-
Efficacy and safety of high-frequency repetitive transcranial magnetic stimulation (rTMS) for migraine: a meta-analysis of randomized controlled trials.Acta Neurol Belg. 2024 Aug;124(4):1167-1176. doi: 10.1007/s13760-024-02570-5. Epub 2024 May 15. Acta Neurol Belg. 2024. PMID: 38748342
-
New perspectives on migraine treatment: a review of the mechanisms and effects of complementary and alternative therapies.Front Neurol. 2024 May 9;15:1372509. doi: 10.3389/fneur.2024.1372509. eCollection 2024. Front Neurol. 2024. PMID: 38784897 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous